Medlinker
Medical Alliance is a post of physician social service platform.
Medlinker, founded in June, 2014 and headquartered in Chengdu, is a chronic disease management platform. Established by Wang Shirui, the company has received financings from Sensegain Asset Management, Sequoia Capital China Fund, China Capital Zhongcai Fund Management and so on. Rivals that have direct and indirect competition with Medlinker globally include Duodianyun, etc.
We-Linking Raised Over CNY 10 Mn in Angel Round
Intraoperative Neurophysiological Monitoring Equipment Developer NeuroFlag Closed An Angel Round
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
ZD Medtech Raised Over CNY 100 Mn in Series B
Smart Powered Bionic Prosthetic Star BionicM Nets Over CNY 10 Mn
Medical Technology Company MacroLux Nets Nearly CNY 100 Mn in Series A
ForLong Biotech Nets Over CNY 100 Mn in Series A
CytoCan Corp. Nets CNY 10 Mn in Seed Round
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Apr 18, 2024 01:25 PM
Haier Biomedical 'Smart Blood City Network' Lands in Brazil
Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.
Apr 15, 2024 03:45 PM
Fine Vision Completes Angel Financing Round Worth Nearly CNY 50 Mn
Levostar Completes Pre-A Financing Round to Further Invest in CGT
YingHe Neuro Raises Over CNY 100 Mn in Angel Round
D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline
EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.
Apr 12, 2024 06:05 PM
How the Hospital Ecosystem of Medlinker is Shaping the Future of China's Healthcare
Actually, it is a huge market to dig into a particular disease. For example, the company had collaborated with Gilead Science, a research-based biopharmaceutical company focused on innovative medicines, in exploring and developing DTP(Direct To Patient) solutions of Hepatitis C.
Nov 22, 2018 11:30 PM
BlissBio Nets Over CNY 100 Mn in Series B+
Medical Equipment Company PowerSite Nets Over CNY 100 Mn in Series B
Equipment Company Keyto Nets Over CNY 100 Mn in Series C
IVD Company Bioantibody Nets Over CNY 100 Mn in Series A